What is the 13F Pro Quality Score for BNTC?

13F Pro ranks Benitec Biopharma Inc. (BNTC) on the 13F Pro Quality Score, a 0–100 composite of 32 fundamental signals including return on invested capital, free cash flow consistency, balance-sheet strength, earnings quality, growth durability, and valuation discipline. The score refreshes after each 10-K and 10-Q filing on SEC EDGAR. View BNTC's current score at https://13fpro.ai/research/BNTC (free sign-up required for the full ranking).

Where does 13F Pro source BNTC data?

All Benitec Biopharma Inc. fundamentals and ownership data come directly from SEC EDGAR. Benitec Biopharma Inc. files with the SEC under CIK 1808898. 13F Pro ingests XBRL financial facts from 10-K and 10-Q filings, Form 13F-HR institutional holdings, and Form 4 insider transactions, with no third-party rewrites or estimates.

What sector is BNTC in?

Benitec Biopharma Inc. (BNTC) is classified in the Healthcare sector. 13F Pro publishes sector-level fund flow analysis and quality leaders at https://13fpro.ai/research/sector/healthcare.

How often is BNTC research updated on 13F Pro?

BNTC's fundamentals refresh within hours of each new 10-K or 10-Q filing on SEC EDGAR. Institutional ownership updates after each quarterly 13F filing window. Insider transactions update after each Form 4 filing. The 13F Pro Quality Score recalculates after every fundamentals refresh.

Benitec Biopharma Inc.(BNTC)Stock Analysis

AI analysis on 2,800+ stocks →Deep AI analysis on 2,800+ stocks →

Healthcare →Nasdaq

Institutional-grade research for retail investors

SEC EDGAR: CIK 1808898 BNTC stock profile & AI dashboard →

13F Pro Quality Score

Not in ranked universe

Below size threshold

Quality rankings require at least $50M annual revenue or $250M total assets to filter out micro-caps and shell companies. This company reported $12.2M in revenue.

Financial data, filings, and institutional holdings below are still tracked in full — only the proprietary quality composite is unavailable for this name.

BNTC Stock Analysis & AI Quality Score

AI stock analysis and institutional research for Benitec Biopharma Inc. (BNTC), a Healthcare sector company. BNTC is not currently included in 13F Pro's AI-ranked quality universe — quality rankings require at least $50m annual revenue or $250m total assets to filter out micro-caps and shell companies. this company reported $12.2m in revenue. Based on the latest XBRL financial filings (Q3 2026), Benitec Biopharma Inc. reports net income of $-11.9M, free cash flow of $-4.5M. Top institutional holders of BNTC by reported 13-F value include SUVRETTA CAPITAL MANAGEMENT,, JANUS HENDERSON GROUP PLC, FRANKLIN RESOURCES, based on the most recent SEC filings. BNTC trades on the Nasdaq exchange and files with the SEC under CIK 1808898. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate BNTC daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for Benitec Biopharma Inc. directly from SEC EDGAR.

Revenue

Q3 2026

$0.00

Net Income

Q3 2026

$-11.9M

Free Cash Flow

Q3 2026

$-4.5M

Revenue & Net Income

Earnings Per Share

Key Financials Over Time

Export Financial Table · Pro+

Revenue

+2.7% YoY

$75.0KFY 2023

FY20 $102.0KFY21 $59.0KFY22 $73.0KFY23 $75.0K

Net Income

-7.4% YoY

$-19.6MFY 2023

FY20 $-8.3MFY21 $-13.9MFY22 $-18.2MFY23 $-19.6M

Operating Income

-6.9% YoY

$-19.1MFY 2023

FY20 $-8.3MFY21 $-13.6MFY22 $-17.9MFY23 $-19.1M

EPS (Diluted)

+62.7% YoY

$-14.12FY 2023

FY20 —FY21 $-3.23FY22 $-37.88FY23 $-14.12

Total Assets

-25.3% YoY

$4.5MFY 2023

FY20 $11.6MFY21 $21.4MFY22 $6.0MFY23 $4.5M

Op. Cash Flow

-13.3% YoY

$-18.0MFY 2023

FY20 $-7.5MFY21 $-12.8MFY22 $-15.9MFY23 $-18.0M

Metric	FY 2023	FY 2022	FY 2021	FY 2020	FY 2018
Revenue	$75.0K +2.7%	$73.0K +23.7%	$59.0K -42.2%	$102.0K	—
Net Income	$-19.6M -7.4%	$-18.2M -31.2%	$-13.9M -67.8%	$-8.3M	—
Operating Income	$-19.1M -6.9%	$-17.9M -31.3%	$-13.6M -64.2%	$-8.3M	—
EPS (Diluted)	$-14.12 +62.7%	$-37.88 -1072.8%	$-3.23	—	—
Total Assets	$4.5M -25.3%	$6.0M -72.1%	$21.4M +84.5%	$11.6M	—
Operating Cash Flow	$-18.0M -13.3%	$-15.9M -23.9%	$-12.8M -70.3%	$-7.5M	—

AI Insight: BNTC Financial Trends

Benitec remains pre-revenue with accelerating operating losses and no clear path to profitability; equity base expanded sharply in Q4 2025 but burn rate remains unsustainable.

• Operating losses widened from $6M in Q2 2024 to $14M in Q1 2026, indicating accelerating R&D spend without revenue offset.

• Equity jumped from $76M in Q4 2024 to $187M in Q4 2025, suggesting major capital raise to fund clinical development.

• Operating cash burn moderated from $8M in Q4 2024 to $4M in Q1 2026, but company remains loss-making with zero revenue.

⚠ Net losses spiked to $16M in Q2 2025 before moderating; sustainability of current burn rate depends entirely on pipeline success.

⚠ Equity declined from $187M in Q4 2025 to $183M in Q1 2026 despite zero revenue, signaling ongoing dilution from operations.

AI Insight: BNTC Ratio Trends

Benitec remains unprofitable across all return metrics, but Q4 2025–Q1 2026 show stabilization after severe Q2 2025 deterioration.

• ROIC bottomed at -70.6% in Q2 2025, then recovered to -29.6% in Q1 2026—a 41pp improvement in nine months.

• ROE and ROA similarly show steady improvement: ROE from -66.4% (Q2 2025) to -26.0% (Q1 2026).

• TTM ROIC at -29.4% reflects weighted drag from Q2 2025 trough; latest quarter metrics indicate ongoing trajectory shift.

⚠ Company remains deeply unprofitable across all periods; Q1 2026 returns are negative across ROE, ROA, and ROIC.

⚠ Sustained negative returns signal ongoing cash burn and value destruction; profitability inflection not yet evident.

Get alerted when BNTC's score changes

Free account: watchlist tracking, the daily AI brief, and the AI screener.

Passwordless sign-in · Payments by Stripe · Auth by Clerk

Available Research

13F Pro tracks comprehensive data for Benitec Biopharma Inc. including:

SEC EDGAR filings (10-K, 10-Q, 8-K)

XBRL financial facts (revenue, EPS, margins)

Insider transactions (Form 4)

Institutional 13F holdings

Quality rankings (32 signals)

AI analyst debates & daily meetings

Historical financial trends

Peer comparison & sector analysis

Top Institutional Holders of BNTC

SUVRETTA CAPITAL MANAGEMENT, LLC
$123.0M11,548,351 sh
JANUS HENDERSON GROUP PLC
$30.7M2,876,380 sh
FRANKLIN RESOURCES INC
$25.3M2,378,159 sh
ADAGE CAPITAL PARTNERS GP, L.L.C.
$22.6M2,120,672 sh
RA CAPITAL MANAGEMENT, L.P.
$19.7M1,850,000 sh
Nantahala Capital Management, LLC
$15.3M1,438,371 sh
BlackRock, Inc.
$12.6M1,185,741 sh
VANGUARD CAPITAL MANAGEMENT LLC
$9.9M931,556 sh
INFINITUM ASSET MANAGEMENT, LLC
$9.8M923,006 sh
Alyeska Investment Group, L.P.
$8.0M750,000 sh

Fund	Value	Shares
SUVRETTA CAPITAL MANAGEMENT, LLC	$123.0M	11,548,351
JANUS HENDERSON GROUP PLC	$30.7M	2,876,380
FRANKLIN RESOURCES INC	$25.3M	2,378,159
ADAGE CAPITAL PARTNERS GP, L.L.C.	$22.6M	2,120,672
RA CAPITAL MANAGEMENT, L.P.	$19.7M	1,850,000
Nantahala Capital Management, LLC	$15.3M	1,438,371
BlackRock, Inc.	$12.6M	1,185,741
VANGUARD CAPITAL MANAGEMENT LLC	$9.9M	931,556
INFINITUM ASSET MANAGEMENT, LLC	$9.8M	923,006
Alyeska Investment Group, L.P.	$8.0M	750,000

More Healthcare Companies

View all Healthcare →

AAPG

ASCENTAGE PHARMA GROUP INTERNATIONAL

AARD

Aardvark Therapeutics, Inc.

ABBV

AbbVie Inc.

ABCL

AbCellera Biologics Inc.

ABEO

ABEONA THERAPEUTICS INC.

ABOS

Acumen Pharmaceuticals, Inc.

ABPWW

Abpro Holdings, Inc.

ABSI

Absci Corp

Put BNTC on your watchlist

Track score changes the day Benitec Biopharma Inc. files with the SEC, follow the hedge funds that own it, screen 2,800+ AI-scored stocks, and get the daily brief — free.

View Pricing

Free tier includes 13F data, economic indicators, and market overview. Pro starts at $6.67/mo (billed annually).

Passwordless sign-in · Payments by Stripe · Auth by Clerk

Popular Research

AAPL

Apple

MSFT

Microsoft

NVDA

NVIDIA

GOOG

Alphabet

AMZN

Amazon

Is BNTC a good stock to buy?

13F Pro's AI-powered analysis of Benitec Biopharma Inc. (BNTC) draws on SEC EDGAR-sourced fundamentals, institutional 13F holdings, and insider Form 4 transactions in the Healthcare sector (listed on Nasdaq). The 32-signal AI Quality Score, current rank, and full bull/bear verdict for BNTC are available on the BNTC stock profile dashboard — with the same data, AI insights, ratios, and institutional activity refreshed after every 10-K, 10-Q, 13F, and Form 4 filing.

Which hedge funds own BNTC?

Institutional investors are required to disclose their holdings quarterly via SEC Form 13F. 13F Pro aggregates these filings to show which hedge funds, mutual funds, and asset managers are buying or selling BNTC. Combined with insider transaction data from Form 4 filings and AI-powered analysis from 10 specialized research agents, 13F Pro provides a comprehensive view of Benitec Biopharma Inc.'s investment landscape.